Presentations by Event

Resistance to Sulbactam Durlobactam in Clinical Isolates of Acinetobacter baumannii is Rare and Maps to PBP3

Samir Moussa

Program(s): durlobactam (etx2514)

Discovery of a Novel Series of Penicillin-binding Protein 3 Inhibitors to Treat Pseudomonas aeruginosa Infections: Rational Design of Biochemical Potency and Bacterial Permeation

Thomas Durand-Reville

Scientific Overview of Entasis Pipeline

Ruben Tommasi, ASM Microbe 2019

The Novel β-lactamase Inhibitor ETX2514 Restores Sulbactam Activity against Recent, Globally Diverse Clinical Isolates of Acinetobacter baumannii calcoaceticus Complex Isolates

Sarah McLeod, ASM Microbe 2019

Program(s): durlobactam (etx2514)

Novel Therapies Targeting Drug-Resistant Gonorrhea

John Mueller, ASM Microbe 2019

Program(s): zoliflodacin (etx0914)

Cefpodoxime-ETX1317 Susceptibility is Unaffected by Ceftazidime-Avibactam Resistance Mutations V240G, D179Y and D179Y/T243M in KPC-3 b-Lactamase

Adam Shapiro, ASM Microbe 2019

Program(s): etx0282

The Novel β-lactamase Inhibitor ETX1317 Restores the Activity of Cefpodoxime Against Drug-Resistant Enterobacteriaceae

Sarah McLeod, ASM Microbe 2019

Program(s): etx0282

Pharmacokinetics/Pharmacodynamics and Phase 3 Dose Projection For the Novel β lactamase Inhibitor ETX2514 in Combination with Sulbactam Against Acinetobacter baumannii calcoaceticus Complex (ABC)

John O'Donnell, ASM Microbe 2019

Program(s): durlobactam (etx2514)